Bayer Kogenate FS Long-Acting Formula Expected To Drive Future Biologic Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
The company plans to initiate Phase III studies this year for the first long-acting recombinant Factor VIII.
You may also be interested in...
Bayer Kogenate FS Free Trial Launches With Bio-Set Needle Free System
Hemophilia A treatment promotion incorporates risk information after an earlier promotion drew FDA criticism.
Bayer Kogenate FS Free Trial Launches With Bio-Set Needle Free System
Hemophilia A treatment promotion incorporates risk information after an earlier promotion drew FDA criticism.
Next For Nexavar: Bayer/Onyx Initiate Phase III Lung Cancer Trial
Study will evaluate sorafenib in combination with carboplatin and paclitaxel.